BJABHomo sapiens (Human)Cancer cell line
Also known as: BJA-B-1, BJA-B1, BJAB-1, BJA-B, BJAb
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_5711 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Groin[UBERON:UBERON_0008337] |
Donor Information
| Age | 5 |
|---|---|
| Age Category | Pediatric |
| Sex | Female |
Disease Information
| Disease | Burkitt lymphoma |
|---|---|
| Lineage | Lymphoid |
| Subtype | Burkitt Lymphoma |
| OncoTree Code | BL |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-001447_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.His193Arg (c.578A>G) | Unspecified | Somatic mutation acquired during proliferation | PubMed=28445466 |
| Gene fusion | CLTC | KMT2A-CLTC | - | - | PubMed=31160637 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
The LL-100 panel: 100 cell lines for blood cancer studies.";
MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.
Sci. Rep. 9:8218-8218(2019).
Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology.
Lossos I.S., Landgraf R., Vega-Vazquez F.
Cancer Lett. 436:149-158(2018).
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Clin. Cancer Res. 24:3967-3980(2018).
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Pham L.V.
Oncotarget 9:346-360(2018).
Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Tucker H.O.
Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
Leukemia 27:1381-1390(2013).
Genetic heterogeneity of diffuse large B-cell lymphoma.";
Dunson D.B., Dave S.S.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.
Nature 463:88-92(2010).
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 25:275-278(2001).
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Leuk. Res. 24:255-262(2000).
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Quentmeier H., Drexler H.G.
Leukemia 10:142-149(1996).
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
J. Immunol. 150:5418-5428(1993).
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
Magrath I.T.
FASEB J. 7:951-956(1993).
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Ann. Hum. Genet. 44:119-133(1980).
Growth of human malignant lymphoid cell lines in serum-free medium.";
Uittenbogaart C.H., Cantor Y., Fahey J.L.
In Vitro 19:67-72(1983).
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
Parsons R.G.
J. Immunol. 129:1336-1342(1982).
Glycoproteins and sialyl transferase of human B lymphoblastoid cell lines.
Lui S.W.-L., Ng M.-H.
Arch. Virol. 63:31-41(1980).
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Ehlin-Henriksson B., Klein G.
Int. J. Cancer 33:459-463(1984).
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.
Sundstrom C.
Proc. Natl. Acad. Sci. U.S.A. 71:3283-3286(1974).
Constitutive production of B cell differentiation factor-like activity by human T and B cell lines.
Kanowith-Klein S., Saxon A., Uittenbogaart C.H.
Eur. J. Immunol. 17:593-598(1987).
p53 is frequently mutated in Burkitt's lymphoma cell lines.";
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
EMBO J. 10:2879-2887(1991).
Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.
Menezes J., Leibold W., Klein G., Clements G.B.
Biomedicine 22:276-284(1975).
Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Fresen K.-O., zur Hausen H.
Int. J. Cancer 17:161-166(1976).
Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro.
Steinitz M., Klein G.
Proc. Natl. Acad. Sci. U.S.A. 72:3518-3520(1975).